Cargando…
Cost-Utility Analysis: Current Methodological Issues and Future Perspectives
The use of cost–effectiveness as final criterion in the reimbursement process for listing of new pharmaceuticals can be questioned from a scientific and policy point of view. There is a lack of consensus on main methodological issues and consequently we may question the appropriateness of the use of...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Research Foundation
2011
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3113167/ https://www.ncbi.nlm.nih.gov/pubmed/21713127 http://dx.doi.org/10.3389/fphar.2011.00029 |